1209 IMO-2125 PLUS RIBAVIRIN GIVES SUBSTANTIAL FIRST-DOSE VIRAL LOAD REDUCTIONS, CUMULATIVE ANTI-VIRAL EFFECT, IS WELL TOLERATED IN NAIVE GENOTYPE1 HCV PATIENTS: A PHASE 1 TRIAL

1209 IMO-2125 PLUS RIBAVIRIN GIVES SUBSTANTIAL FIRST-DOSE VIRAL LOAD REDUCTIONS, CUMULATIVE ANTI-VIRAL EFFECT, IS WELL TOLERATED IN NAIVE GENOTYPE1 HCV PATIENTS: A PHASE 1 TRIAL D. Guyader, P. Bogomolov, Z. Kobalava, V. Moiseev, J. Szlavik, B. Astruc, I. Varkonyi, T. Sullivan, K. Horgan, A. Bexon, R. Arbeit. Service des Maladies du Foie, Universite de Rennes, Rennes, France; Moscow Regional Clinical Research Institute, City Clinical Hospital #64, Clinical Hospital #3 of Medical Centre of Mayor Administration and Moscow Government, Moscow, Russia; Department of Immunology, St. Laszlo Hospital, Budapest, Hungary; Biotrial, Rennes, France; Institute of Clinical Pharmacology Infectology & Allergology, Kenezy Hospital, Debrecen, Hungary; Idera Pharmaceuticals, Cambridge, MA, USA E-mail: dominique.guyader@univ-rennes1.fr